Last reviewed · How we verify
NCT05194475
Metabolic Effects of a Thermogenic Ready-to-drink Beverage
NA trial testing Thermogenic Ready-to-drink Beverage in Metabolic Rate in 28 participants. Completed in 6 May 2022.
6 May 2022
Quick facts
| Lead sponsor | Texas Tech University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 28 |
| Start date | 18 January 2022 |
| Primary completion | 6 May 2022 |
| Estimated completion | 6 May 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Thermogenic Ready-to-drink Beverage
- Placebo Ready-to-drink Beverage
Conditions studied
- Metabolic Rate — all drugs for Metabolic Rate →
- Metabolism — all drugs for Metabolism →
Sponsor
Texas Tech University
Who can join
Adults 18 to 40, any sex, with Metabolic Rate or Metabolism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a randomized, double-blind, placebo-controlled crossover trial examining the metabolic effects of a novel ready-to-drink (RTD) beverage. Healthy adult males and females will be recruited for participation. Each participant will complete two conditions in random order: 1) RTD thermogenic beverage ; and 2) placebo (consisting of the flavoring of the thermogenic beverage without the active ingredients). In each condition, metabolism (resting metabolic rate), hemodynamic (heart rate and blood pressure), and subjective (ratings of energy, focus, concentration, alertness, and mood) assessments will be completed at baseline, 30 minutes after beverage consumption, and 30 minutes after the second round of assessments.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Effects of a ready-to-drink thermogenic beverage on resting energy expenditure, hemodynamic function, and subjective outcomes.
Rodriguez C, Stratton MT, Harty PS, Siedler MR, et al · · 2023 · cited 5× · PMID 37162193 · DOI 10.1080/15502783.2023.2211958 -
Proceedings of the Nineteenth International Society of Sports Nutrition (ISSN) Conference and Expo.
VanDusseldorp T, Kerksick CM, Bustillo E, Kalman D, et al · · 2023 · cited 1× · PMID 37018511 · DOI 10.1080/15502783.2023.2187955
Verify or expand the search:
- PubMed search for NCT05194475
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Texas Tech University trials
Trials by the same sponsor.
- NCT06755827 — Pilot Testing a Novel Approach to Pediatric Obesity Treatment · Phase 1, PHASE2 · recruiting
- NCT07239609 — ACT for Individuals With MNCD and Their Care Partners · Phase 1 · not yet recruiting
- NCT06919536 — Controlled Feeding With 24 Hour Recall · completed
- NCT06055322 — Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD · NA · recruiting
- NCT06865196 — Investigating a Brief Virtual Seminar Series for Parents of Teens Ages 13-17 · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05194475 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Texas Tech University
- Last refreshed: 9 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05194475.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing